Synthetic Biology at Scale: Less Disruption, More Cohesion
For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity
Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients
Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Ingredient Production
Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical production sites.
Antheia secures new funding to boost pharmaceutical ingredients production
The company secured funding through government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside strategic investment from In-Q-Tel and Echo
Antheia Announces New Funding to Support Domestic Production of Critical Pharmaceutical Ingredients
Company awarded government project agreement to onshore key pharmaceutical supply chains, alongside strategic investment from In-Q-Tel and Echo
Addressing a Root Cause of Global Drug Shortages
The years-long journey medicines take from the farm to the pharmacy is a delicate one, vulnerable to extreme weather, mechanical failures, logistical and shipping delays, and geopolitical issues.
Antheia at SynBioBeta 2024: Scaling Highly Engineered Strains
Antheia was a proud sponsor of this year’s SynBioBeta, the Global Synthetic Biology Conference hosted annually in the San Francisco Bay Area.
Introducing Pavel Aronov, Senior Director, Bioanalytics
Pavel and his team have developed the processes to accurately measure the quantity of our biosynthetic KSMs and APIs produced via biomanufacturing, which is no small feat when working with biological products
U.S. Secretary of State Antony J. Blinken Visits Antheia to Discuss Biotechnology Innovation
In early May, U.S. Secretary of State Antony J. Blinken visited Antheia, HQ in Menlo Park, California for a tour of our labs and a panel discussion with innovators in the biotechnology industry
Secretary of State Antony J. Blinken Tours Antheia, Discusses the Importance of Biotechnology Innovation in the United States
Visit demonstrates U.S. commitment to bolstering the domestic biotechnology industry and onshoring critical supply chains, including pharmaceuticals Menlo Park, Calif., May 6, 2024 – Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today hosted Secretary of State Antony J. Blinken for a tour of its state of the art labs, as well as […]